Deutsche Bank Maintains Buy Rating and $67 PT on Regeneron Pharmaceuticals

A report from Deutsche Bank reiterates its Buy rating and $67 price target on Regeneron Pharmaceuticals REGN. In the report, Deutsche Bank writes, “Efficacy data from recently unblinded HARBOR study did not support initiation of further high dose clinical studies and the company will be discussing 0.5mg PRN (as needed) dosing with the regulators. In our opinion, this indicates that 0.5 mg is the optimal dose of Lucentis and increasing the dose does not improve vision in wet-AMD patients." REGN closed yesterday at $63.